HAYWARD, Calif., Jun 11, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) patients at the 32nd European Cystic Fibrosis Conference in Brest, France.
POSTER NUMBER: # 196
ABSTRACT TITLE: Pharmacokinetics and Antibacterial Activity of Inhaled Liposomal Ciprofloxacin Hydrochloride in Healthy Volunteers and in Cystic Fibrosis (CF) patients
AUTHORS: Paul Bruinenberg MD, Babatunde Otulana MD, Jim Blanchard PhD, David Cipolla Msc, John Wilson MD*, David Serisier MD**, Aradigm Corporation, Hayward, CA. * The Alfred Hospital Melbourne Australia, ** Mater Adult Hospital, Brisbane, Australia
SCHEDULED: Thursday, June 11, 2009 through Saturday, June 13, 2009.
The results demonstrated in both healthy volunteers and cystic fibrosis patients similar pharmacokinetics of inhaled liposomal ciprofloxacin, with a long systemic elimination half life (t½) of ~10.5 hours supporting a once-daily dosing allowing for less frequent dosing than current inhaled antibiotic regimes. As reported before, this treatment was effective to result in highly significant reduction in the sputum of Pseudomonas Aeruginosa colony forming units (CFU), an objective measure of the reduction in pulmonary bacterial load in the CF patients. The promising efficacy data is also supported by the high concentration of ciprofloxacin found in the sputum of CF patients following treatment with inhaled liposomal ciprofloxacin.
Ciprofloxacin is a widely prescribed antibiotic to treat infections of the lung frequently experienced by CF patients. It is often preferred because of its broad-spectrum anti-bacterial action. The available oral and intravenous formulations of the drug are used to treat episodes of acute exacerbations of lung infections. Aradigm's once-a-day novel inhaled formulation of ciprofloxacin delivered in liposomes is to be used for chronic maintenance therapy as it is expected to achieve higher antibiotic concentration at the site of infection and relatively low systemic antibiotic concentrations to minimize side-effects.
About the 32nd European Cystic Fibrosis Conference
The International Conference of the American Thoracic Society (ATS) is the leading scientific meeting organized by European Cystic Fibrosis Society where CF and pulmonary physicians, researchers and allied health professionals around the world gather to learn from each other and build collaborations.
More information about the 32nd European Cystic Fibrosis Conference can be found at http://www.ecfs.eu/brest2009
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, COPD, inhalation anthrax infections and smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the timing and results of clinical trials as well as the other risks detailed in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including Aradigm's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.
SOURCE: Aradigm Corporation
Paul Bruinenberg MD, 510-265-8838
Copyright Business Wire 2009